Answers are grounded in this paper and cite their sources.
Microsatellite-stable (MSS) metastatic colorectal cancer (CRC) is largely refractory to immune checkpoint inhibitors, highlighting the need for immunomodulatory-combination strategies. Preclinical and clinical evidence suggest that inhibition of the MEK and VEGF pathways may sensitize MSS tumors to PD-1 blockade by reshaping the tumor immune microenvironment (TIME). Here, we evaluated the antitumor and immunologic effects of combined MEK, PD-1, and VEGFR2 inhibition using matched human-immune system patient-derived xenograft models generated from patients enrolled in a parallel phase II clinical trial. Six distinct MSS CRC PDX models were implanted into humanized BALB/c‑Rag2 − / − Il2rγ − / − SIRPα NOD mice and treated with vehicle, binimetinib alone, binimetinib plus pembrolizumab, or the triple combination of binimetinib, pembrolizumab and the VEGFR2 inhibitor DC101. Triple therapy reduced tumor growth relative to control and monotherapy, though the responses were heterogeneous across PDXs. Treatment was associated with increased intratumoral human T-cell infiltration, enrichment of effector memory and multifunctional cytotoxic CD4 + and CD8 + T-cells, and reduced regulatory T-cell frequency in responding tumors. Immune correlates observed in HIS-PDX models, including increased effector memory CD8 + T cells and reduced TIGIT-expressing CD8 + T-cells, parallel biomarkers associated with disease control in the matched clinical trial. In contrast, MEK inhibitor monotherapy had fewer cytotoxic CD8 T-cells. These findings demonstrate that combined MEK, PD-1, and VEGF pathway inhibition can reprogram the TIME and elicit antitumor immunity in a subset of MSS CRCs, supporting rational combination immunotherapy approaches and biomarker-driven patient selection. Furthermore, testing in the HIS-mouse model shows tumor heterogeneous responses and can recapitulate immune tumor responses observed in the clinic. The data generated in this study are available upon request from the corresponding author and on ClinicalTrials.gov (NCT03475004), as a community-recognized, structured repository does not exist.
No takes yet. Share an insight, caveat, or question.
Lang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: